Wayne C Koff

USPTO Granted Patents = 25 (Patent Applications = 4)

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 8 (Patent Applications = 14)

Average Co-Inventor Count = 5.9

ph-index = 5

Forward Citations = 72(Granted Patents)

Location History:

Stony Brook, NJ (US) (2003)
New York, NY (US) (2018 - 2022)
Stony Brook, NY (US) (2012 - 2024)

Company Filing History:

24 out of 68

International Aids Vaccine Initiative

patents

19 out of 1,187

The Scripps Research Institute

patents

14 out of 28

Theraclone Sciences, Inc.

The United States of America, As Represented by the Secretary, Department of Health and Human Services

patents

6. 1 out of 832,843

Other

patents

where one patent can have more than one assignee

Years Active: 2003-2025

Loading Chart...

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12410243 - Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies (2025-09-09),

2. 12312396 - Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity (2025-05-27),

3. RE50268 - Broadly neutralizing antibody and uses thereof (2025-01-14),

4. 12018067 - Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity (2024-06-25),

5. 11845789 - Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies (2023-12-19),

6. 11584789 - Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity (2023-02-21),

7. 11319362 - Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies (2022-05-03),

8. RE49037 - Broadly neutralizing antibody and uses thereof (2022-04-18),

9. 10894080 - Transgenic VERO-CD4/CCR5 cell line (2021-01-19),

10. 10865234 - Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity (2020-12-15),

11. 10836811 - Broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibody (2020-11-17),

12. 10407493 - Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity (2019-09-10),

13. 10279027 - Transgenic Vero-CD4/CCR5 cell line (2019-05-07),

14. 10239934 - Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity (2019-03-26),

15. 10093720 - Broadly neutralizing antibody and uses thereof (2018-10-09),

Title: Inventor Wayne C Koff - Revolutionizing the World of Biotechnology

Introduction: Wayne C Koff, a distinguished inventor hailing from New York, NY, has made significant contributions to the field of biotechnology through his innovative creations and groundbreaking patents.

Latest Patents: Wayne C Koff's latest patents include cutting-edge technologies in vaccine development, genetic engineering, and drug delivery systems, showcasing his commitment to advancing healthcare solutions for global challenges.

Career Highlights: With a career spanning over two decades, Wayne C Koff has held key positions in renowned biotech companies and research institutions, leading teams to develop life-saving innovations that have reshaped the industry.

Collaborations: Throughout his career, Wayne C Koff has collaborated with top scientists, researchers, and pharmaceutical companies worldwide, fostering a culture of innovation and knowledge-sharing to drive progress in biotechnology.

Conclusion: Wayne C Koff's passion for pushing the boundaries of biotechnology, coupled with his relentless pursuit of excellence, solidifies his position as a visionary inventor whose work continues to impact the world positively.

This text is generated by artificial intelligence and may not be accurate.